Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma

被引:2
|
作者
Liu, Tong [1 ]
Meng, Guorui [1 ]
Ma, Shihui [1 ]
You, Junqi [1 ]
Yu, Liang [1 ]
He, Risheng [1 ]
Zhao, Xudong [1 ]
Cui, Yunfu [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
hepatocellular carcinoma; immune checkpoint inhibitors; immunotherapy; tumor immune microenvironment; review; OPEN-LABEL; INFUSION CHEMOTHERAPY; PLUS; MULTICENTER; BEVACIZUMAB; SINTILIMAB; LENVATINIB; EFFICACY; THERAPY; SAFETY;
D O I
10.3389/fimmu.2024.1455716
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Among primary liver cancers, hepatocellular carcinoma is the most common pathological type. Its onset is insidious, and most patients have no obvious discomfort in the early stage, so it is found late, and the opportunity for surgical radical treatment is lost, resulting in a poor prognosis. With the introduction of molecular-targeted drugs represented by sorafenib, patients with middle- and late-stage liver cancer have regained the light of day. However, their therapeutic efficacy is relatively low due to the limited target of drug action, toxic side effects, and other reasons. At this time, the emergence of immunotherapy represented by immune checkpoint inhibitors (ICIs) well breaks this embarrassing situation, which mainly achieves the anti-tumor purpose by improving the tumor immune microenvironment. Currently, ICI monotherapy, as well as combination therapy, has been widely used in the clinic, further prolonging the survival of patients with advanced hepatocellular carcinoma. This article reviews the development of monotherapy and combination therapy for ICIs in advanced hepatocellular carcinoma and the latest research progress.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle
    Sukowati, Caecilia
    Cabral, Loraine Kay D.
    Tiribelli, Claudio
    ANNALS OF HEPATOLOGY, 2022, 27 (05)
  • [42] Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
    Hassan Mohammed Abushukair
    Anwaar Saeed
    World Journal of Gastrointestinal Oncology, 2022, 14 (06) : 1210 - 1212
  • [43] Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Bai, Jing
    Liang, Ping
    Li, Qian
    Feng, Rui
    Liu, Jiang
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2021, 16 (02) : 239 - 248
  • [44] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
    Liu, Xiufeng
    Qin, Shukui
    ONCOLOGIST, 2019, 24 : S3 - S10
  • [45] Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Longo, Vito
    Brunetti, Oronzo
    Gnoni, Antonio
    Licchetta, Antonella
    Delcuratolo, Sabina
    Memeo, Riccardo
    Solimando, Antonio Giovanni
    Argentiero, Antonella
    MEDICINA-LITHUANIA, 2019, 55 (10):
  • [46] Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Dyhl-Polk, Anne
    Mikkelsen, Marta Kramer
    Ladekarl, Morten
    Nielsen, Dorte Lisbet
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (12)
  • [47] Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
    Abushukair, Hassan Mohammed
    Saeed, Anwaar
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (06) : 1210 - 1212
  • [48] Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
    Lee, J.
    Ng, K.
    Wong, L.
    Ang, A.
    Tan, S. H.
    Tai, D.
    Choo, S. P.
    ANNALS OF ONCOLOGY, 2019, 30 : 23 - 23
  • [49] Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
    Ng, Kennedy Yao Yi
    Wong, Lawrence Wen Jun
    Ang, Andrea Jing Shi
    Lee, Ailica Wan Xin
    Tay, Desiree Shu Hui
    Tan, Jack Jie En
    Tan, Sze Huey
    Choo, Su Pin
    Tai, David Wai-Meng
    Lee, Joycelyn Jie Xin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 (03) : 312 - 319
  • [50] Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
    Huang, Jin-Tao
    Zhong, Bin-Yan
    Jiang, Nan
    Li, Wan-Ci
    Zhang, Shuai
    Yin, Yu
    Yang, Jun
    Shen, Jian
    Wang, Wan-Sheng
    Zhu, Xiao-Li
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 : 1217 - 1228